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1. Introduction 
RNA interference is an evolutionary conserved mechanism of specific gene silencing 
induced by double stranded RNA homologous to the target mRNA. Small interfering RNAs 
(siRNAs) are widely used for the control of gene expression in molecular biology and 
experimental pharmacology. Currently, siRNAs are successfully used for the validation of 
potent drug targets for anti-cancer therapy. However, application of siRNAs as therapeutics 
is limited by their sensitivity to ribonucleases, poor cellular uptake and rapid size-mediated 
renal clearance. These challenges must be overcome to develop a successful siRNA-based 
drug. Many of these limitations could be resolved with the use of chemical modifications 
improving the siRNA properties. 
This review examines recent data regarding principals of the design of siRNA for the 
silencing of therapeutically relevant genes. A particular focus will be made on chemical 
modifications and their impact on siRNA potency, nuclease resistance and duration of the 
silencing effect. The types of chemical modifications, their location in siRNA structure 
influence siRNA properties in different modes: modulation of the interaction with RNAi 
proteins, the thermal stability and thermoasymmetry of the duplex and the sensitivity to the 
degradation by ribonucleases.  
Special attention will be paid to the design of siRNA for the silencing of thermodynamically 
unfavorable targets: mutant and chimerical genes. In this case the utilization of computer 
algorithms for the selection of active siRNA cannot be applied. Modification of siRNA 
structure aimed at the correction of the thermoasymmetry by incorporation of nucleotide 
substitutions, blocking incorporation of the sense strand in the RISC complex by truncation 
of one overhang or inactivation of the sense strand can be successfully used. Mismatches in 
the central part of the duplex can facilitate the cleavage and dissociation of the “passenger” 
(sense) strand, whereas selective chemical modification protects the non-perfect duplex 
from accelerated degradation. 
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Peptides, steroids and other hydrophobic lipid groups can be attached to siRNA, extending 
the siRNA circulation time and enhancing direct cellular uptake. The potential of 
bioconjugation of siRNA with different biogenic molecules in altering the bioavailability 
and distribution of siRNAs following in vivo delivery will be discussed. The combination of 
these approaches can lead to the development of siRNAs with therapeutic value. 
2. Mechanism of RNAi 
RNAi phenomenon was found during transfection of dsRNAs in C.elegans [1] and is 
inherent in different organisms (flies, vertebrates, higher plants [2, 3, 4]). RNAi mechanism 
was initially examined in details in Drosophila melanogaster, but later it was found that the 
mechanism is highly conservative between the organisms. There are two stages of RNAi 
(fig. 1): at the first stage (phase of initiation) specific ribonuclease Dicer binds to and cleaves 
long dsRNAs yielding short (21-23 nt) duplexes with 2-overhanged nucleotides at the 3’-
ends (or siRNAs); at the second stage (effector phase) siRNAs molecules incorporate into 
multiprotein complex (RISC – RNA-induced silencing complex). One of siRNA strands 
("passanger") undergo cleavage and dissociation from the complex upon RISC activation, 
the other strand ("guide") remains in the complex. Activated complex RISC* specifically 
binds to RNA target and cleaves it (fig. 1) [5, 6, 7, 8, 9, 10] .  Long dsRNAs (> 30 bp) activate 
the innate immune response in the mammalian cells (except for non-differentiated or low 
differentiated cells) resulting in non-specific RNA degradation by RNase L, activation of  
 
Figure 1. Scheme of RNAi. A. Initiation phase B. Effector phase.  
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protein kinase PKR that inhibits translation. The expression of numerous genes, including 
genes encoding interferons and cytokines, alters [11, 12]. Thus, sequence-specific decrease of 
target mRNA level is not observed. It was found that RNAi in mammalian cells can be 
induced by chemically or enzymatically (in vitro) synthesized siRNAs or endogenously 
expressed siRNAs 19-21 bp in length. These siRNAs mimic the products of long dsRNAs 
processing by Dicer and can be involved directly into the effector phase of RNAi mechanism 
passing the phase of initiation (fig. 1) [13, 14, 15, 16, 17]. 
The selection of the "guide" strand is a key step determining the efficacy of RNAi induced 
by synthetic siRNAs. At the first step of RISC* assembly the intermediate complex RLC 
(RISC Loading Complex) consisting of Dicer, siRNA and R2D2 (D.melanogaster) or TRBP [18, 
19, 20] (Homo sapiens) forms (fig. 2 A). R2D2 protein along with its human analog contains 
two dsRNA-binding domains and a Dicer binding domain.  
 
Figure 2. RISC* assembly. A. RLC-complex, consisting of Dicer, dsRNA-binding protein, R2D2 and 
siRNA. B. Interaction of Ago2 with RLC. C. RISC* formation. 
Dicer contains dsRNA-binding domain and PAZ-domain (PIWI/Argonaute/Zwille), that has 
an affinity to 3’-overhangs of siRNA [21, 22]. It was detected that R2D2 preferably binds with 
more thermodynamic stable flank of the siRNA duplex, whereas Dicer interacts with less 
stable siRNA flank [20, 23, 24, 25]. The orientation of siRNA relative to the protein complex 
Dicer-R2D2 determines the positioning of siRNA in the complex with Ago2 (a catalytic part of 
RISC*) (fig. 2 B). Ago2 is a protein of Argonaute family, containing PAZ and PIWI domains. 
The structure of PIWI domain similar to that of RNase H determines endoribonuclease activity 
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of PIWI [26, 27]. Ago2 cleaves the one of the siRNA strand (“passenger” strand), another 
strand (“guide” strand) remains into the RISC* and guides the target RNA recognition and 
cleavage (fig. 2 C). The structure of the complex containing siRNA and Ago2 effects the 
selection of the strand (sense or antisense) that incorporates into RISC*, hence, determines the 
efficacy of mRNA-target cleavage. Evidently, the antisense strand that is homologous to the 
sequence of mRNA-target has to be “guide” strand in order to cleave mRNA. Ago2 replaces 
the Dicer-R2D2 dimer (fig. 2 B), interacting with Dicer via PAZ domain [28] whereas the 
phosphate group at the 5’-end of the strand from the Dicer side (“guide” strand) interacts with 
PIWI domain that contains Mg2+ ion and basic amino acids. 
The nucleotides located at 2 - 6 positions of the “guide” strand stabilizes the interaction 
between siRNA and Ago2 [29, 30, 31]. The presence of the phosphate at the 5’-end of the 
“guide” strand is essential for RISC* assembly [32, 33]. This orientation of siRNA with 
respect to catalytic PIWI-domain provides the cleavage of the complementary strand 
(“passenger” strand) between 9th and 10th nucleotides that facilitates the strand 
dissociation (fig. 2 C) [34, 35]. Ago2 and the “guide” strand are the main components of 
RISC* [36], however, other proteins could also interact with RISC* [10]. Thus, the difference 
between thermodynamic stability of the duplex termini (thermodynamic asymmetry) 
determines the orientation of Dicer-R2D2 dimer and as a result, the structure of Ago2-
siRNA complex. Therefore, thermodynamic properties of siRNA play a key role in the 
strand selection [20, 23, 24, 25] providing the preferential selection of the strand with low 
thermodynamic stability at the 5’-end of the duplex as the “guide” strand [37, 38]. 
It was shown, that the perfect match between 2 - 12 nt of the “guide” strand (corresponding 
to one turn of dsRNA helix) and the target mRNA is essential for effective recognition and 
binding of RISC* with mRNA target [39]. The mechanism of RNA-target cleavage (occurs 
between 10th and 11th nt relative to the 5’-end of the “guide” strand [40]) and the following 
dissociation are similar to that of the “passenger” strand (described above). Cleaved target 
RNA and the “passenger” strand are degraded by ribonucleases after dissociation, whereas 
RISC* becomes available for acting in catalytic mode [7, 9, 17, 41]. Unlike antisense 
oligodeoxyribonucleotides (ODN), whose efficacy of action is determined by the efficacy of 
ODN hybridization with mRNA-target (fig. 3) [42], the formation of the duplex between the 
"guide" strand of siRNA and mRNA- target occurs due to the helicase activity of RISC* and 
virtually independent from the hybridization properties of the oligoribonucleotide [43]. 
Silencing of gene expression by siRNAs is observed at the much lower ON concentrations 
than in the case of antisense ODN (IC50 for siRNAs is 100 – 1000 times lower, than IC50 for 
antisense ODNs) [43, 44]. 
Another mechanism of RISC activation - “bypass” route - employs the dissociation of the 
siRNA strands without preliminary cleavage of the sense strand by Ago2 [35]. This type of 
RISC activation is inherent in miRNAs, containing unpaired bases in the central part, critical 
for Ago2 endoribonuclease activity (fig. 4). Moreover, the “bypass” rout was observed for 
siRNAs with chemically modified nucleotides surrounding the cleavage site (between 9th 
and 10th nt of the “passenger” strand [45]) impeding Ago2 action [34, 35, 46]. Silencing of 
gene expression proceeds via the arrest of mRNA translation, since RISC* binds to mRNA-
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target together with translation suppressor proteins (for example, helicase RCK/p54 from 
DEAD box family) [47]. Complex of mRNA and proteins is deposited in “P-bodies” 
(processing bodies - distinct foci in the cytoplasm involved in mRNA turnover) [48]. In “P-
bodies” mRNA decapping followed by ribonuclease cleavage occurs. In the other cases, 
mRNA complexed with proteins can be deposited in “P-bodies” for a long time without 
degradation (fig. 4). Later, mRNAs can escape from “P-bodies” and be involved in 
translation machinery or can be degraded in a described above manner [10]. 
 
Figure 3. Silencing of gene expression by antisense ODNs: A. The degradation of the duplexes: 
ODN / mRNA or ODN / pre-mRNA by RNase H. B. Inhibition of mRNA translation or pre-mRNA 
splicing by ODNs those are not RNase H substrates [43].  
The “bypass” mechanism of RISC activation is less efficient than the “classical” one, since in 
this case RISC* does not act in a catalytic mode. The efficiency of RISC* assembly also is 
limited by the low rate of ATP-dependent dissociation of intact siRNA strands [35, 33, 39]. 
Thermodynamic stability siRNA duplex is an additional parameter determining the efficiency 
of RISC* assembly, hence, the efficiency of RNAi. Earlier developed algorithms for the 
selection of active siRNA sequences suggest selection of mRNA targets with approximately 
50% GC-content. In the later studies, the percentage of G+C nucleotides in the structure of 
effective siRNAs varied from 30 to 50% [49, 50]. It was shown that low thermodynamic 
stability of the central part of the duplex (from 9th to 14th nt counting from 5’-end of the 
antisense strand) arising from AU-rich sequences or the presence of mismatches is a hallmark 
of active siRNAs [37]. The average difference between Gibbs energy of central parts of active 
and inactive siRNAs was found to be about 1.6 kcal/mol. Unlike thermodynamic asymmetry, 
unstable center of duplex is not a sufficient criteria for selection of active siRNA [37].  
Structural features of mRNA-target also effects the RNAi efficacy [51, 52, 53, 54]. The 
availability of the mRNA sequence for binding with siRNA (the absence of the hairpins in the 
secondary structure or overlapping with the binding regions of regulatory factors) as well as in 
the case of the ribozymes and the antisense ODN [55] can influence the silencing efficacy. In 
order to prove this, siRNAs targeted to mRNA sequences with different binding availability 
were synthesized [53]. It was shown that siRNAs targeted to the region of the initiation of 
translation or the 3’-end of mRNA-target were inactive. Whereas siRNAs targeted to the 
regions forming the hairpins displayed low and average silencing activity. As expected high-
performance siRNAs were those targeted to unstructured regions of mRNA [51, 52, 54].  
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Thus, the analysis of the secondary structure of mRNA-target and thermodynamic properties 
of siRNA duplex play important role in the selection of active inhibitors of gene expression. 
 
Figure 4. Scheme of RNAi with the “bypass” rout of RISC* assembly (miRNA-like action). RISC* binds 
with mRNA-target (n is equal 1, if the antisense strand is fully complementary to mRNA) [10].  
3. Chemical modifications: The influence on RNAi efficacy 
Currently, the development of RNAi-based drugs is an important aim in pharmacology. The 
optimization of siRNAs structure is required for biomedical applications; chemical 
modifications could be successfully used for this purpose. Different types of chemical 
modifications were widely used in antisense ODNs before the discovery of RNAi [42]. The 
data collected in these experiments can be applied for optimization of the properties of 
siRNAs. There are two types of factors affecting both antisense ODNs and siRNAs efficacy: 
systemic factors that act on the level of the organism and intracellular factors defining the 
activity of the therapeutics in the cells. The first type of factors includes: i) fast (approx. 5 
min) siRNA elimination from organism resulted from its hydrophobicity and size of the 
molecule (approx. 14 kDa) [56, 57], ii) high nuclease sensitivity of siRNA [58, 59, 60, 61, 62] 
and iii) inefficient or/and non-specific delivery into target cells [63]. Intracellular factors are 
related to RISC assembly and the efficiency of binding to and cleaving the target. 
3.1. Chemical modifications of the nucleotides 
3.1.1. Modifications of ribose (furanose) ring  
All ribose modifications can be divided in two main groups: the modifications related to the 
replacement of hydrogen atoms in furanose by different groups and structural modifications 
of the furanose cycle.   
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3.1.1.1. Substituents in furanose 
The 2’-OH group of the ribose is the main target for modification, since this group is involved 
in the phosphodiester bonds cleavage by endoribonucleases via trans-etherification 
mechanism [64]. Thus, the modification of 2’-OH defends siRNA against ribonucleases [62]. 
The size of the substituent is an important characteristic determining its tolerance by RNAi 
machinery. The small groups (2’-O-methyl (2’-O-Me), 2’-fluoro (2’-F) etc.) (fig. 5 А) virtually 
do not disturb the conformation of siRNA duplex and are better tolerated than bulky groups: 
2’-O-methoxyethyl (2’-O-MOE), 2’-O-allyl (2’-O-allyl) etc. The replacement of 2’-OH by 
electrophilic groups also stabilizes C3’-endo conformation of the ribose (fig. 6) which 
corresponds to A-helix geometry of the duplex obligatory for effective RNAi [58]. This sugar 
conformation arrange for the axial location of the substituents reducing total energy of the 
system and increasing the affinity to the complementary RNA target. As a result the duplex 
melting temperature (ΔTm) increases approximately 1 0С per modification [65]. 
2’-O-methyl modification is one of the widely used 2’- modifications for the enhancement of 
nuclease resistance of siRNA [59, 62] and impeding the induction of the interferon response 
in eukaryotic cells [64, 66, 67, 68, 69, 70]. Obviously, the number and location of the modified 
nucleotides in the duplex are crucial for the silencing. The increase of the number of 
modifications was shown to decrease the silencing activity of siRNAs; totally modified 
siRNAs frequently had no activity [58, 59, 71]. However, in a number of experiments the 
activity of siRNA with the totally modified sense strand was compatible with that of 
unmodified analog [72, 73]. This can be related to functional unequivalence of siRNA 
strands [74, 75]. The introduction of 2 - 4 2’-О-Me modifications in the both strands of 
siRNA is well tolerated. Moreover, in the case of selective modification of the nuclease-
sensitive sites within siRNA the increase of the duplex nuclease resistance and prolonged 
silencing were detected [59].  
The C3’-endo conformation could be stabilized by introduction of 2’-F-modified nucleotides 
in siRNA (fig. 5 A). Since fluorine atom is more electronegative than oxygen atom, the 
increase of the binding affinity between siRNA strands and target RNA (ΔTm 2 – 4 0С per 
modification) is observed [65]. Remarkably, the silencing activity of 2’-F-modified siRNAs 
virtually does not depend on the number of modifications in contrast to 2’-O-Me-modified 
siRNAs. The silencing activity of siRNAs with 2’-F-modifications in the sense and the 
antisense strands was compatible with that of unmodified analogs [76]. The replacement of 
pyrimidine nucleotides in the duplex with 2’-F-analogs was well tolerated by RNAi 
machinery both in vitro [46, 77, 73] and in vivo [78]. The silencing activity of siRNA 
containing 2’-F modifications located in the site of Ago2 cleavage and unmodified analog 
was similar [79], as well as long-term silencing effects in vivo of modified siRNAs and 
unmodified analogs [78]. It should be noted that epimers of 2’-F-nucleotides (2’-fluoro-β-D-
arabinonucleotides, FANA (fig. 5 A)) with DNA-like C2’-endo-conformation of furanose 
cycle [80] (fig. 7) introduced in siRNA structure also improve the nuclease resistance of the 
duplex. It was found that partial modification of both strands with FANA or total 
modification with FANA of the sense strand of siRNAs ensure the A-geometry helix [81] 
and effective RNAi. These modifications were shown to alter the duplex thermodynamic 
stability insignificantly [76]. 
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Figure 5. Analogs of nucleotides and nucleosides used for siRNA modification. A. Substituents in 
furanose. B. Structural modifications of furanose cycle. C. Backbone modifications. “B” – base (А – C). 
D. Nucleobase modifications. “R” – ribose residue.  
 
Figure 6. C3’-endo conformation of the ribose with the 2’-substituent. R – electron-acceptor group. 
 
Figure 7. C2’-endo (DNA-like) conformation of ribose with the substituent (R) in 2’-position.  
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On the contrary, the replacement of ribonucleotides of siRNAs with deoxyribonucleotides 
characterized by C2’-endo-conformation of the furanose cycle (fig. 5 A) reduces their 
affinity to mRNA-target (ΔTm -0.5 0С per modification) (fig. 7) [65]. Mainly, 
deoxyribonucleotides are used for the defense of siRNA overhangs from exonucleases [13, 
59]. However, the modification of the other duplex regions does not impede effective 
RNAi [40, 82]. The introduction of deoxyribonucleotides in the duplex region responsible 
for the recognition of the target mRNA, so called "seed" region (about 8 nt. from the 5’-
end of the antisense strand [29]) results in the increase of siRNA specificity since lesser 
stability of DNA/RNA hybrids as compared with RNA duplex [82]. siRNAs with the 
totally modified antisense or sense strands had no activity regardless of preferable for 
RNAi A-helix geometry of the duplexes [32]. 
Introduction of the bulky groups in the 2’-position of the furanose causes the 
conformational disturbance of the siRNA duplexes resulting in the decrease of siRNA 
silencing activity [76]. However, the modification of duplex termini and overhangs with 
2’-О-methoxyethyl (2’-O-MOE) or 2’-O-allyl groups (fig. 5 A) was tolerant [46, 83, 84]. The 
random replacement of 2’-OH in the both strands of the siRNA (up to 70 %) by 2,4-
dinitrophenyl ethers (2’-O-DNP) (fig. 5 A) causes the increase of the silencing activity. 
Since the thermodynamic stability of the modified duplex was comparable with that of 
unmodified duplex [85] (that indicates the similar hybridization properties [86]), the 
observed effect may be related to the increase of the nuclease resistance and cellular 
uptake of the modified siRNA [85, 86, 87]. In order to increase the nuclease resistance of 
the siRNA duplexes, other chemical modifications - 2’-aminoethoxymethyl (2’-AEM), 2’-
aminopropoxymethyl (2’-APM), 2’-aminoethyl (2’-EA), 2’-cyanoethyl (2’-СE), 2’-
guanidinoethyl (2’-GE) etc.- may be used (fig. 5 А). It was shown that totally modified 
siRNAs were inactive, whereas the silencing activity of the partially modified siRNAs 
depends on the location of the modifications in the duplex structure [88]. 
Introduction of the modifications at the 4’-position of the furanose results in the slight 
increase of the RNA-duplex termostability (ΔTm 1 0С per modification) [89, 90]. Usually the 
4’-thio (4’-S) ribonucleosides (fig. 5 А) are used for modification of siRNA, especially, at the 
termini [91, 92, 93]. The replacement of the several ribonucleotides at the 5’-end of the 
antisense strand [91] or four ribonucleotides at the sense strand termini and at the 3’-end of 
the antisense strand [93] by 4’-S- analogs only slightly decrease the silencing activity of 
siRNAs, whereas the modification of the central part of the duplex significant inhibits RNAi 
[91, 92]. The introduction of the 4’-S-modifications in siRNA structure increases nuclease 
resistance of the duplex and improves the pharmacokinetics of siRNA. Unfortunately, this 
modification simultaneously increases the binding of siRNAs with blood serum components 
and increases their cytotoxicity [65]. 
3.1.1.2. Structural modifications of the furanose ring  
This type of modifications includes bicyclic derivatives of the nucleotides (LNA, ENA, 
CLNA, CENA, AENA et al.), acyclic nucleotides (UNA, PNA) or nucleotides containing 
pyranose ring (ANA, HNA) instead of ribose (fig. 5 B). LNA and ENA (2'-О,4'-С-methylene- 
 Practical Applications in Biomedical Engineering 196 
and 2'-О,4'-С-ethylene bicyclic nucleotide analogs are the frequently used bicyclic 
derivatives which provide the significant increase of the duplex thermostability (ΔTm up to 
10 0С per modification) [94, 95]. The ribose in LNA and ENA is fixed in C3’-endo-
conformation (fig. 6) due to the methylene or ethylene “bridge” between 2’- and 4’-
positions, respectively.  
Experimental data on the activity of LNA- and ENA-modified siRNAs are contradictory. In 
some cases modifications of the 5’- and/or 3’-ends of the both siRNA strands were well 
tolerant [65, 96, 97, 98], whereas in the other studies ENA-analogs at the 3’-end of the sense 
strand of siRNAs reduced or abolished the silencing activity [74]. The difference in activity 
may be connected with the difference in the thermodynamic asymmetry of the modified 
siRNA [37, 38].  The replacement of the several ribonucleotides with LNA in the antisense 
strand was shown to be well tolerant [71, 96], whereas extensive modification was tolerant 
only in the case of sisiRNA with segmented sense strand [99] (see section 1.3.5).  
The thermodynamic stability and nuclease resistance of the siRNA could be increased by 
introduction of HNA and ANA nucleotides with pyranose ring (hexitol nucleic acid and 
altritol nucleic acid, respectively (fig. 5 B)) instead of ribose [100, 101]. The modified duplex 
contaning these analogs adopts the A-helix geometry [100], however, the location of the 
ANA- or HNA-analogs in siRNA structure is critical for silencing activity. Remarkably, the 
introduction of the ANA- or HNA-analogs at the 3’-termini of one or both strands maintain 
or increase the silencing activity [102, 103]. The presence of ANA-analogs at the 5’-end of the 
antisense strand substantially decreased the siRNA activity. It was suggested that 
modifications at the 5’-end of the antisense strand impede the action of cellular kinases due 
to steric obstacles [103]. The decrease of the phosphorylation efficacy of the 5’-terminal 
nucleotide of the antisense strand is critical for efficient interaction of siRNA with Ago2 
PIWI domain followed by mRNA-target cleavage [32, 33]. siRNAs with HNA or ANA-
analogs of nucleotides in the central part of the sense strand display the effective gene 
silencing, whereas, similar modifications of the antisense strand substantialy decreased the 
siRNA activity [88, 103]. 
In contrast to siRNA duplex stabilizing modifications, the presence of acyclic nucleotide 
analogs (UNA) (fig. 5 B) in the siRNA increase the conformational flexibility of the duplex 
and decrease its thermodynamic stability (ΔTm -5 to -8 °С per modification). The location of 
the UNA-analogs in siRNA was shown to play a key role, since one modification can result 
in the significant reduction or augmentation of the silencing activity of siRNA [99, 104]. It 
was suggested that the replacement of ribonucleotides at the 3’-end of the sense strand 
increases the duplex thermodynamic asymmetry and acquires antisense strand 
incorporation into RISC* [104, 105]. It was found experimentally that the introduction of 1 - 
3 UNA nucleotides at the 3’-end of the sense strand, including the 3’-overhangs, increase to 
some extent the siRNA activity [106, 107]. Quite the opposite, the modification of the first 
and the second positions of the “guide” strand abolishes the 5’-end phosphorylation and 
reduce siRNA silencing activity.  
Peptide nucleic acids analogs (PNA) containing N-(2-aminoethyl)-glycin polyamide 
backbone could be used for modification of siRNA. It was shown that in the antiparallel 
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PNA/RNA duplex RNA adopts the right-handed helix characterized by anticonformation at 
the N-glycosidic bond and C3’-endo-conformation of the ribose [108], with the similar to the 
RNA-like A-helix geometry [58]. PNAs are stable in the human blood serum as well as in 
the cellular extract; they are resistant to protein kinase A and several types of peptidases 
[109]. It was found that the introduction of PNA-analogs in the sense and / or in the 
antisense strands of the duplex increase nuclease resistance of siRNA. The increase of the 
siRNA silencing activity was observed when modifications were introduced in the sense 
strand. In the other cases the activity of PNA-containing siRNA was comparable with 
activity of the unmodified siRNA [110]. Due to the functional inequivalence of siRNA 
strands the modifications in the sense strand a better tolerated than modifications in the 
antisense strand. 
Thus, virtually all ribose modifications provide the increase of the nuclease resistance of 
siRNA. However, the optimization of their number and location in the duplex structure 
(depending on the type of modification) is required to make them tolerable in the process of 
RNAi.  
3.1.2. Backbone modifications  
This type of modifications includes the replacement of phosphate group (PO) with 
phosphorothioate (PS) or boranophosphonate (PB) groups, the replacement of the 3’,5’-
phosphodiester bond with 2',5'-bond or the amide bond instead of the ester bond (fig. 5 C). 
All of these modifications increase the nuclease resistance of siRNA, however their impact 
on the efficacy of RNAi is varied [76]. PS-modification is known to reduce the melting 
temperature of the duplex and oligoribonucleotide binding affinity [71]. However, the 
experimental data related to the activity of PS-modified siRNAs are discrepant. The 
comparable silencing activity of the PS-modified siRNAs and their unmodified analogs was 
shown in the studies [83,111], whereas in the other studies the silencing activity of the PS-
modified siRNAs was lower, than that of their unmodified analogs [58, 73, 112]. The 
modification of the central part of the duplex decreases siRNA activity [113]. Remarkably, 
siRNAs with blunt 3’-ends containing totally PS-modified one or both strands were active 
[73]. However, high binding affinity of the phosphorothioate analogs to serum albumin, 
IgG, IgM, lactoferrin and the cellular membrane receptors is disadvantageous [114]. It 
results in the development of toxic effects both in vitro and in vivo, even siRNAs containing 
alternate PS-analogs were toxic in cell cultures [83, 111]. Introduction of boranophosphonate 
analogs (fig. 5 C) increases nuclease resistance of the duplex as compared with PS-
containing and unmodified siRNA [65] and increases RNAi efficacy. It was found that an 
optimal position for PB-modifications is the terminal region of the sense strand of siRNA, 
whereas the modification of the central part of the duplex resulted in the significant 
decrease of silencing activity [65]. This effect is likely connected with the inhibition of the 
sense strand cleavage by Ago2 during RISC* formation. The replacement of the 3’,5’- by 
2’,5’-phosphodiester bond or 3’,5’-amide bond (fig. 5 C) increases the nuclease resistance of 
the duplex and is tolerant when located in the sense strand [115] or the 3’-overhangs of 
siRNA [116]. 
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Thus, the most promising modification of the siRNA backbone is the boranophosphonate 
modification, since it provides the increase of the nuclease resistance of the duplex and its 
silencing activity and is not accompanied by the development of toxic effects. However, the 
price of PB-analogs limits their usage. 
3.1.3. The chemical modifications of the nucleobases  
In contrast to the other types of modifications, the modifications of heterocyclic bases 
(nucleobases) have no influence on the nuclease resistance of RNAi. Earlier it was found that 
the presence of modified nucleobases in the antisense ODN altered their hybridization 
properties [42]. It is known that the replacement of the uridine by 5-bromo- or 5-iodouridine 
(fig. 5 D) improves their ability to interact with adenine owing to the increase of the acidity of 
the imine and results in the stabilization of the base pair [117]. The replacement of the adenine 
by 2,6-diaminopurine results in the formation of the additional H-bond, hence, in the 
stabilization of the nucleotide base pair [58]. At the start, it was suggested that the introduction 
of these analogs in the antisense strand of siRNA will enhances its binding affinity to mRNA 
and increases the RNAi efficacy. Unexpectedly, the decrease of silencing activity of modified 
siRNA in comparison with unmodified ones was observed. This effect is possibly related with 
the decrease of the dissociation rate of siRNA duplex on the step of RISC* formation [58]. The 
replacement of uridine by 2-thiouridine (s2U) or pseudouridine (ψ) (fig. 5 D) provides the 
increase of the duplex thermodynamic stability due to the stabilization of the ribose in the C3’-
endo-conformation (fig. 6) [118, 119]. Dihydrouridine (D) contains non-aromatic ring that does 
not participate in staking interactions (fig. 7) which resulted in the destabilization of siRNA 
[120], but one substitution with D at the 3’-end of the sense or the antisense strand does not 
change siRNA silencing activity. The replacement of U by Ψ and s2U at the 3’-end of the sense 
strand reduces the silencing activity, whereas introduction of the same modification at the 3’-
end of the antisense strand creates favorable thermodynamic asymmetry and provides siRNAs 
with higher activities than the parent siRNA. Thus, these modifications could be applied for 
the design of thermoasymmetric siRNAs [120] (see section 3.3).  
3.2. Chemical modification of siRNA termini  
This type of modifications includes the modification of the nucleotides at the 3’-overhangs 
and the 5’-ends of the duplex. These modifications could be used for the solution  of 
different problems: i) to increase the nuclease resistance of siRNA towards exoribonucleases 
(inverted 3’-3’ or 5’-5’ deoxyriboses [61, 121] (fig. 8), dideoxycytosine [122], ENA-analog of 
the thymidine [74] etc.), ii) to facilitate asymmetric RISC* assembly (the replacement of the 
5’-OH by 5’-OMe group in the terminal nucleoside [123]) and  ii) to provide the efficient 
accumulation of siRNA in cells (attachment of lipophilic molecules [57, 124, 125], folic acid 
[126], peptides [14, 127, 128], aptamers [129]). The fluorescent residues [111] and biotin [130] 
are widely used as a termini modification for siRNA detection.  
The type of the applicable terminal modification has to be selected experimentally. In many 
cases the modification of the 5’- and 3’-ends of the sense (“passenger”) strand is well 
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tolerated [59, 131, 111, 130], however the data on modification of the antisense (“guide”) 
strand are discrepant. It is known that the phosphorylation of 5’-OH groups of the antisense 
strands of synthetic siRNAs by the kinases [33, 122] is essential for interaction with PIWI-
domain of Ago2 and for correct selection of the “guide” strand [29, 30, 31]. Therefore the 
replacement of the 5’-OH group by the 5’-OMe in the sense strand blocks its 
phosphorylation and the incorporation into RISC* as a “guide” strand [123]. On the other 
hand, the same modification of the antisense strand resulted in the decrease of siRNA 
silencing activity [59, 131, 122]. However, the attachment of the fluorescein residue to the 5’-
phosphate of the antisense strand via hexamethylene linker is well tolerated [111], 
suggesting that this modification does not prevent the interactions of the 5’-terminal 
phosphate of siRNA with PIWI-domain. The 3’-end of the antisense strand recognized by 
PAZ-domains of Dicer and Ago2 [21] is less sensitive to modification [14, 33, 59]. It was 
shown that the attachment of puromycin or biotin to the 3’-end of the antisense strand [130] 
or the replacement of the 3’-terminal ribonucleotide by ddC, or the attachment of the 
aminopropyl linker via phosphodiester bond [122] virtually does not change the silencing 
activity. However, the introduction of the 2-hydroxyethylphosphate, ENA-analog of 
thymidine [74]  or fluorescent dyes [111] at the 3’-end of the antisense strand abolished the 
silencing. The replacement of the terminal nucleotides of siRNA in both strands by 5’-5’- or 
3’-3’-dioxyribose (fig. 8) results in the increase of the nuclease resistance and does not 
reduce the silencing activity [59, 61].  
 
Figure 8. Inverted deoxyribose applied for the protection of 5’- or 3’-termini of siRNA.   
3.2.1. Bioconjugates 
Anionic siRNA cannot effectively pass through the electrostatic and hydrophobic barriers of 
the cellular membrane to enter the cytoplasm and to induce RNAi. Conjugation of siRNAs 
with the lipophilic molecules (cholesterol, derivatives of the oleic, lithocholic and lauric 
acids), peptides, antibodies, aptamers and other compounds is an effective tool to overcome 
this problem [132, 133]. The cholesterol was suggested as the first candidate for conjugation, 
since the natural mechanisms of cholesterol transport exist in mammalian organisms. 
Apolipoprotein B (ApoB) expressed in the liver and intestine cells is involved in the 
assembly and secretion of the lipid-protein particles known as very-low-density lipoproteins 
(VLDL) and low-density lipoproteins (LDL) and in the transport and metabolism of the 
cholesterol. Since ApoB located on the cellular surface is specific to LDL-receptors, 
responsible for the delivery of the lipoproteins into cell [132, 134], it was suggested that 
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LDL-receptors could deliver the cholesterol-conjugated siRNAs inside the cells via receptor-
mediated endocytosis. It was proved experimentally that LDL-receptors bind with the LDL-
particles preliminary associated with cholesterol-conjugated siRNA or the conjugate of 
siRNA and the oleic or lithocholic acids, however the mechanism of their penetration into 
cell is not well-defined [125] (Table 1). Moreover, the involvement of the transmembrane  
 
siRNA 
conjugate 1) 
Modification 2) 
Linker, 
site of attachment to siRNA
Cell or 
target 
organ 
Target 
gene 
Silen-
cing 
effi-
cacy, % 
Ref. 
Lipo-siRNA 
trans-4-hydroxy proline 
linker at the 3’-end of the 
sense strand 
mouse 
liver 
Apo-B-1 55-25 125 
Сhol-siRNA 
 
 
 
aminocaproic acid-
pyrrolidine linker at the 3’-
end of the sense strand 
mouse 
liver 
Apo-B-1 50 57 
-(CH2)-S-S-(CH2)6-  at the 5’-
end of the sense strand 
mouse 
lungs 
P38 
MAP 
kinase 
40 127 
6-aminohexyl at the 5’-end of 
the sense strand 
β-
Gal/Huh
-7 
cells 
β-Gal 55 124 
Folate-
siRNA 
at the 5’-end of the sense 
strand 
HeLa 
cells 
n.d. 3) n.d. 126 
ТАТ-siRNA YGRKKRRQRRR 
N-terminal Cys-HN-(CH2)3-
at the 3’-end of the antisense 
strand 
HeLa 
cells 
GFP 
CDK9 
60 – 70 14 
C-terminal Cys –S-(CH2)6- 
at the 5’-end of the sense 
strand 
Lungs of 
mouse 
P38 
MAP 
kinase 
40 127 
Penetratin-
siRNA 
CRQIKIWFQNRRMKWKK 
N-terminal Cys-S-(CH2)6- 
at the 5’-end of the sense 
strand 
COS-7
cells 
F.lucifera
se 
60 128 
C-terminal Cys –S-(CH2)x- 
at the 5’-end of the sense 
strand 
Lungs of 
mouse 
P38 
MAP 
kinase 
20 127 
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Transportan-
siRNA 
CLIKKALAALAKLNIKLLYGASNLTWG
N-terminal Cys-S-(CH2)6- 
at the 5’-end of the sense 
strand 
COS-7
cells 
F.lucifera
se 
50 128 
Aptamer-
siRNA 
at the 5’-end of the sense 
strand 4) 
LNCaP 
and PC-
3 cells 
Bcl-2 
PLK1 
80 129 
Antibody-
siRNA 
Antibodies to insulin receptor 
biotin-tetraethylene glycol 
at the 3’-end of the sense 
strand 
HEK 293
cells 
F.lucife-
rase 
> 90 141 
Antibodies to transferrin receptor 
biotin-tetraethylene glycol 
at the 3’- or 5’-end of the 
sense strand 
Brain of 
mouse 
69 – 81 142 
1) Lipo – lipophilic residues, Chol – cholesterol residue. 
2) siRNA with linker are denoted «R». 
3) In this investigation the biological activity of the conjugate was not measured (n.d.). 
4) The conjugate of siRNA and aptamer synthesized by in vivo transcription (without linker). 
Table 1. Bioconjugates of siRNAs 
protein SID-1 in the transport of the lipophilic conjugates was also shown [135]. It was  
suggested that SID-1 facilitates the dsRNA penetration into cells forming the channels for 
diffusion or mediating the interactions with other proteins [125, 135]. The successful use of 
the cholesterol and the derivatives of lithocholic, oleic and lauric acids for siRNA 
modification was demonstrated in vitro [124] and in vivo [57] (Table 1). The conjugate of 
siRNA and cholesterol, attached to the 5’-end of the sense strand, is able to penetrate into 
the human liver cells in the absence of the transfection agents. siRNA bearing cholesterol in 
the sense strand inhibits ß-Gal gene expression more effectively than siRNAs with the 
cholesterol in the antisense strand or in the both strands. In the presence of the transfection 
agent the activity of the unmodified siRNA was comparable with that of the conjugates 
[124]. The accumulation of siRNA-Chol was detected in liver, heart, kidneys, fatty and 
pulmonary tissues after intravenous injection of the radioactively labeled conjugates 
(containing cholesterol at the 3’-end of the sense strand) in mice. It should be noted that cells 
of these organs express LDL-receptors at high level. Other examples of cholesterol-modified 
siRNAs with high penetration ability are presented in the Table 1.  
The conjugation of siRNAs with the peptides could also improve their cellular accumulation 
(Table 1). 11 amino acid cationic peptide derived from cell-permeable Tat protein and 
responsible for its nuclear localization was used in a number of studies [14, 127]. It was 
found that the attachment of this peptide (TAT-peptide) with additional cysteine to the 3’-
end of the antisense strand of siRNA results in its effective accumulation in HeLa cells and 
effective silencing of the target genes EGFP and CDK9 [14]. The endocytosis was suggested 
to be the mechanism of the conjugates penetration into cells [136, 137].  
The addition of the cell penetrating peptides (transportan and penetrantin) to the 5’-end of 
the sense strand of siRNA improves the penetration ability and the silencing activity of anti-
EGFP and anti-GL2 siRNAs in COS-7, C166-GFP, EOMA-GFP and CHO-AA8-Luc Tet-Off 
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cells [128] (Table 1). It was suggested that penetration of the conjugates does not occur via 
pino- or endocytosis, but is mediated by diffusion through plasma membrane [128]. Besides 
the increase of transfection efficacy, the attachment of the peptides to siRNAs may enhance 
their specificity. Bioconjugates of siRNAs with peptides inhibiting the RISC assembly and 
containing specific sequence cleavable by cell-specific peptidases are promising agents for 
cell-specific gene silencing [138]. The efficient inhibition of the exogenous GFP expression 
was observed in choriocarcinoma Jeg-3 cells after electroporation of the conjugate of siRNA 
and a peptide with the “LEVD” sequence recognized by caspase-4, whereas in caspase-4 
deficient HEK 293 cells the conjugate was inactive [138].    
Another approach to the enhancement of siRNA cellular accumulation is the delivery of 
siRNA conjugated with antibodies or aptamers [132]. The aptamers are structured synthetic 
nucleic acids with size less than 15 kDa (Table 1), they can be chemically modified for the 
defense from the nucleases [139]. The penetration of these conjugates occurs via specific 
interactions with receptors on the surface of the target cells, providing the effective cellular 
accumulation of siRNAs [132]. The conjugates of anti-BCL2 or anti-PLK1 (polo-like kinase 1) 
siRNA and PSMA-receptor specific aptamer, effectively penetrate into prostate cancer 
LNCaP cells and induce effective gene silencing [129]. Injection of these conjugates into 
tumor expressing PSMA-receptors results in tumor regression [140]. It was shown also that 
the conjugates of siRNA and anti-transferrin or anti-insulin monoclonal antibodies attached 
to siRNA via streptavidin-biotin linker effectively reduces the exogenous F.luciferase 
expression in HEK 293 cells and rat glial cells implanted in the brain [141, 142] (Table 1).  
The attachment of the folic acid to siRNA is a promising approach to increasing cellular 
uptake of siRNA. These conjugates can penetrate into virtually all human cancer cells, since 
expression of the expression of the folate receptors on the surface of the cancer cells is 
substantially higher than in normal cells [143]. The efficient accumulation of fluorescein-
labeled siRNA with folate attached to the 5’- or 3’-end of the sense strand via disulfide bond 
was observed in solid tumor in mice [126] (Table 1). In the other studies [144, 145]  the 
delivery of siRNA into cells was performed with folate-containing structures. These 
experiments (in vivo and in vitro) verified the advantage of siRNA modification by folate: 
specific delivery into cancer cells and high silencing effect of these siRNAs was observed. 
The introduction of biomolecules in siRNA is one of the promising approaches of non-viral 
delivery. In contrast to other non-viral methods (cationic lipids and polymers, high-pressure 
injections) the advantages of conjugation include the cell-specificity and the absence of toxic 
effect [63, 146, 147, 148, 149]. The employment of cholesterol- and folate-contaning siRNAs 
in vivo is less specific, since LDL- and folate-receptors are expressed by different cells [125, 
150], however, this approach is could be usefully applied when strict cell or tissue selectivity 
is not required.  
3.3. Combination of chemical modifications 
The application of different modifications simultaneously is a widely-used approach for the 
optimization of siRNA properties. Two main strategies are considered in order to increase 
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nuclease resistance of siRNA. The first one is based on the extensive modification of siRNA. In 
this case optimal design of the duplex (i.e. selection of modifications) could be created 
experimentally by the analysis of the data on nuclease resistance and biological activity. For 
example, different types of modifications were used in totally modified siRNA, displaying 
high activity in mice infected with Hepatitis B virus. The sense strand of this siRNA contains 
deoxyribonucleotides instead of the purine ribonucleotides, 2’-F-modifications and 5’-5’- and 
3’-3’-terminal deoxyribonucleotides instead of the pyrimidine bases;  the antisense strand 
contains alternating 2’-F / 2’-O-Me groups; one PO-bond between 3’-terminal nucleotides was 
replaced by PS-bond [61] (Table 2). Other examples of siRNA containing different 
combinations of chemical modifications are presented in the table 2. However, the extensive 
modification of siRNA often is not well-tolerated by RNAi machinery and rather often leads to 
the reduction or blocking of the silencing activity [40, 59, 99]. Therefore, minimization of the 
number of modifications in siRNA structure is required. It was shown, that duplexes with 
limited number of LNA-modifications could be active and as resistant to nucleases as the 
totally modified 2’-O-Me / 2’-F-siRNAs, which were inactive [40, 59, 99, 99] (Table 2). Since 
siRNAs are degraded mainly by endoribonucleases [59], it was suggested that the increase of 
the thermostability will increase the nuclease resistance [99]. On the other hand, it is known 
that the pattern of siRNA degradation in the presence of serum is similar to the cleavage by 
RNase A [62]. Therefore, the selective modification of the nuclease sensitive sites of siRNAs, 
mapped in the presence of serum, represents an alternative approach to the extensive 
modification of siRNA. This rational approach of siRNA modification allows to minimize the 
number of modified nucleotides in the duplex and as a consequence, to maintain its silencing 
activity [76]. The optimization of siRNA design also includes the defense of the 3’-terminal 
nucleotides against exonuclease cleavage (see section 1.2.2).  
The combinations of chemical modifications are used for optimization of other siRNA 
properties. In order to achieve in vivo both the efficient cellular uptake and their high 
nuclease resistance, the 2’-O-Me-modified or/and PS-modified siRNAs conjugated with 
cholesterol were used [57, 151]. In order to increase the thermoasymmetry of the duplex, the 
nucleotide analogs with opposite effect on the siRNA thermostability can be used 
simultaneously. For instance, LNA- and UNA-analogs introduced in siRNA simultaneously 
was shown to enhance the silencing activity of the siRNA due to the increase of 
thermoasymmetry of the duplex: duplex stabilization of the duplex by LNA-analogs at the 
5’-end and destabilization by UNA-analogs at the 3’-end of the sense strand [99].  
The increase of the RNAi efficacy was also observed after stabilization of the 3’-end of the 
antisense strand of siRNA by s2U or ψ analogs and destabilization of the 5’-end by 
introduction of D at the 3’-end of the sense strand [120]. It should be noted that the decrease 
of the thermostability of the duplex at the 3’-end of the sense strand is more preferable in 
comparison with the stabilization of the duplex at the 5’-end of the sense strand if the 
duplex stabilization is not needed [99].  
Thus, in order to optimize siRNA design by chemical modifications the following principles 
should be considered: modifications should provide 1) the RNA-like A-helix geometry of 
the duplex; 2) the access of the terminal 5’-OH group of the antisense strand for  
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1) Bold letters – deoxyribonucleotides, underlined letters – 2’-O-Me, italics – 2’-F-analogs, B_ – 5’-5’-, _B – 3’-3’-inverted 
deoxyribose, underlined bold letters – LNA-analogs, s – phosphorothioate bond between nucleotides. 
2)  “-” data is not available. 
Table 2. Extensive and selective modification of siRNA   
 
siRNA property The role of chemical modification Examples of modifications 
Thermostability 
To increase the thermostability of siRNA by 
providing the optimal conformation of nucleotides 
for base pairing65, 99, 120. 
2’-О-Ме, 2’-F, 2’-F-ANA, 2’-
O-MOE, 2’-O-DNP, 4’-S, 
LNA, ENA et al. 
Thermoasymmetry 
To increase the thermoasymmetry of the duplex by 
the decrease of thermostability at the 3’-flank of the 
sense strand or/and the increase of the 
thermostability at the 5’-flank of the sense strand of 
the duplex 99, 105, 107, 120. 
UNA, LNA, nucleobase 
modifications 
Nuclease resistance 
To increase the duplex nuclease resistance by 
introduction of the chemically modified analogs of 
nucleotides in its structure153,76. 
Virtually all modifications 
Duration of circulation in 
the bloodstream 
To increase siRNA affinity to serum proteins and the 
time of circulation 57, 65. 
PS, 4’-S, Сhol 
Cellular uptake 
To provide the effective mechanisms of siRNA 
penetration: receptor-mediating endocytosis, 
diffusion via cellular membrane or other ways (if the 
mechanism is unknown)153, 86, 126. 
Chol, 2’-O-DNP, 
folate 
Target cellular uptake 
To increase the specificity of uptake by the 
attachment of the molecules with high binding 
affinity to surface of the cells of particular organs and 
tissues154. 
Peptides, 
antibodies, 
aptamers 
Specificity of action 
To increase the specificity of the silencing by: 1) the 
increase of duplex thermoasymmetry99, 105, 107, 120; 2) 
alteration of binding affinity of the antisense strand 
of siRNA to mRNA-target155, 99, 82; 3) the absence of 
receptors providing the activation of immune 
response 64; 4) blocking the phosphorylation of the 5’-
OH group of the sense strand of siRNA 123. 
1) see above; 
2) UNA, 2’-O-Me, 
deoxyribonucleotides 
3) 2’-O-Me 
4) 2’-O-Me 
Table 3. Influence of the chemical modifications on siRNA properties 
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phosphorylation; 3) low thermostability of the 5’-end of the antisense strand, hence, the 
modification has to increase the favorable thermoasymmetry or has no effect on the duplex 
thermostability.  
The information on the influence of chemical modifications on siRNA properties is 
summarized in the table 3.  
4. The impact of the siRNA structure on the efficiency of RNAi  
The investigation of the structures of natural siRNAs formed by dsRNA processing with 
Dicer and endogenous miRNA revealed the common siRNA structures. "Classical" small 
interfering RNA resembles duplexes 18 - 23 bp in length [18, 22, 156, 157] with 2 nt 
overhangs at 3'-ends [40, 45] (fig. 9).  
However, it was clearly demonstrated, that the silencing activity of structurally similar 
duplexes with different sequences varies significantly. As it was mentioned above 
thermodynamic asymmetry of the duplex and to a lesser extend the structure of mRNA 
target determines the siRNA activity [44, 45, 57, 58, 60]. Possibility to optimize the duplex 
structure was demonstrated in a number of publications. Introduction of nucleotide 
substitutions in siRNA, resulting in a formation of non-canonical base pairs or mismatches 
[38, 158, 159] is a perspective approach for the optimization of the thermodynamic 
properties of the duplex. The other approach utilize the inactivation of the sense strand of 
siRNA (for example, segmentation) to guarantee the incorporation of the antisense strand 
into activated RISC* independent from the thermodynamic properties of the duplex [99]. 
The silencing activity of siRNA can be increased by the lengthening of the duplex and 
converting siRNA into Dicer substrate DsiRNA [160, 161] or by the modifications of the 
overhands affecting duplex thermodynamic asymmetry [162]. Single stranded analogs of 
siRNA can be also used as inducers of RNAi, in this case the problem of the strand selection 
does not exist [40, 77]. All mentioned approaches will be described in details below. 
 
Figure 9. Structural repertoire of siRNA. The triangle indicates single stranded nick.  
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4.1. The influence of nucleotide substitutions on the silencing activity of siRNA  
Thermodynamic properties of siRNA play a key role on the stages of RISC activation and 
mRNA target cleavage, determining the efficiency of strand dissociation, strand selection 
and mRNA cleavage. Since that, nucleotide substitutions affecting thermodynamic stability 
of the duplex could change the silencing activity of siRNA.  The nature of the changes 
depends on the type of substitutions and the location of the substitutions in siRNA 
structure. The data on the impact of nucleotide substitutions in the silencing activities of 
siRNAs reported in the literature are summarized in Table 4.  
The kinetics of mRNA cleavage directed by anti-F.luciferase and anti-sod1 siRNA, containing 
nucleotide substitutions in one of the strands of the duplex were exanimated in details in 
[38]. It was shown, that the substitution of cytosine with uracil at the 5’-end of the sense 
strand of anti-F.luciferase siRNA, resulting in U:G pair formation (stabilized by two 
hydrogen bonds)[163]), reduced the target mRNA cleavage rate. At the same time, the rate 
of the antisense RNA (complementary to the first target) cleavage increased substantially. 
The analysis of the binding of siRNA strands with RISC* revealed, that single nucleotide 
substitution at the position 1 of the sense strand reduce the incorporation of the antisense 
strand in the complex, whereas the efficiency of the sense strand incorporation into RISC* 
increased (fig. 10 A).  
Nucleotide substitution at the 3’-end of the sense strand of anti-sod1 siRNA resulting in the 
formation of А:G mismatch (fig. 10 B), caused the opposite effect: the rate of mRNA 
cleavage increased, while the rate of antisense mRNA cleavage decreased. This result 
indicates that the efficiency of the sense strand incorporation into RISC* decreases. The 
observed effect could be caused both by preferential incorporation of the antisense strand 
into RISC complex, and by non-perfect complementarity between the sense strand of siRNA 
and its target (antisense mRNA), but the results of the additional experiments with the 
substitution of G by C at the 5’-end of the antisense strand (fig. 10 B) verified the key role of 
preferential RISC loading [38]. Thus, it was clearly demonstrated, that single nucleotide 
substitutions at the flank regions of siRNA could change the thermodynamic asymmetry 
and to determine the preferential incorporation of one strand into RISC*: destabilization of 
the duplex at the 3’-end of the sense strand increase the activity of siRNA , the 
destabilization of the opposite end of the duplex, reduce the silencing activity [38].  
 
Figure 10. The scheme of the experiment described in 38. А. Substitution at the 5’-end of the sense 
strand of anti-F.luciferase siРНК. B. Substitution at the 3’-end of the sense strand (left) or at the 5’-end of 
the antisense strand (right) of anti-sod1 siRNA.  
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Target, model system Type of 
siRNA 1) 
Substitutions 2,3) Silencing efficiency, 
% 
Reference 
P.luciferase, 
(+2/+ 23), 
plasmid, transfected into 
Hela cells 
1 
 
2 
- 
G1G → U1U 
А19 → U19 
U18А → A18U 
A17UА→U17AU 
C16AUА→U16UAU 
U18А → A18U, G12→U12 
98 
94.5 
99.5 
99.8 
99.8 
99.6 
99 
158 
P.luciferase, 
(+21/+ 43), 
plasmid, transfected into 
Hela cells 
1 
 
2 
 
- 
A1C → U1A 
C19 → U19 
G18C → U18U 
U17GC → A17UU 
C16UGC→U16AUU 
G18C → U18U, G12→U12 
50 
8 
76 
78 
75 
70 
78 
Lamin A/C ,  
(+829/+ 851), 
Hela cells 
 
1 
2 
- 
A18C → U18U, A12→U12 
67.5 
79.5 
Lamin A/C,  
(+608/+ 630), 
Hela cells 
 
1 
2 
- 
C18A → U18U, U12→A12 
79 
92 
Dnm T1,  
(+70/+ 89), 
Hela cells 
 
1 
2 
- 
G18A → U18U, G12→U12 
77.5 
84.5 
Dnm T1,  
(+185/+ 203), 
Hela cells 
 
1 
2 
- 
U18U → A18A, G12→U12 
82.5 
89.5 
R.luciferase/P.luciferase с ,  4) 
plasmid, transfected into 
Hela cells 
1 
 
2 
- 
A1C → U1A 
G18C → U18U 
86 
72 
95 
159 
R.luciferase/ P.luciferase a,
plasmid, transfected into 
Hela cells 
1 
 
2 
- 
C18A → A18U 
C1G → U1U 
92 
89 
20 
F.luciferase, 
plasmid, transfected into 
NIH3T3 cells 
 
1 
- 
G9 → C9 
G6,9 → C6,9 
G6,9,13 → C6,9,13 
G3,6,9,13,17 → C3,6,9,13,17 
60 
57 
56 
30 
15 
74 
MGC29643, 
(+576/+596) 
Неla cells 
1 - 
C8 → G8 
A12 → U12 
C8, A12 → G8, U12 
50 
10 
55 
3 
166 
GPR39, 
(MGC29643 
(+576/+596)а) 
Неla cells 
1 - 
C12 → G12 
A8 → U8 
A8, C12 → U8, G12 
50 
55 
5 
0 
Jagged-1, 
(+3382/+3402) 
plasmid, transfected into 
НЕК 293Т cells 
1 - 
C18 → U18 
C5 A12C15 → U5G12U15 
 
0 
50 
0 
165 
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Target, model system Type of 
siRNA 1) 
Substitutions 2,3) Silencing efficiency, 
% 
Reference 
sod1/F.luciferase c, 
plasmid, transfected into 
НЕК 293 cells 
1 -
G1 → U1 
C19 → A19 
G1 → U1  
C19 → A19
55
0 
70 
70 
0
164 
sod1/F.luciferase a, 
plasmid, transfected into 
НЕК 293 cells 
1 -
G1 → U1  
C19 → A19 
G1 → U1 
C19 → A19
75
75 
45 
40 
80
АPP(L)/luciferase 5), 
plasmid, transfected into 
НЕК 293 cells 
2 -
C18C → U18U 
0
45 
159 
АPP(S)/luciferase, 
plasmid, transfected into 
НЕК 293 cells 
2 -
G18C → U18A 
0
80 
159 
EGFP, 
(+306/+324) 
human lung carcinoma 
H1299 
1 -
G19 → C19 
55
50 
24 
 
EGFP, 
(+396/+414) 
human lung carcinoma 
H1299 
1 -
G19 → A19 
G19 → C19 
G19 → U19 
C19 → A19 
C19 → U19 
C19 → G19 
65
42 
40 
35 
52 
45 
45
F.luciferase,  
plasmid, transfected into 
Неla SS6 cells 
1 -
C1 → A1 
A19 → C19 
A19 → G19 
A19 → U19 
G9 → A9 
G9 → C9 
G9 → U9 
A10 → C10 
other substitutions in the sense 
strand (2 – 8, 12 – 18 positions)
1 b) 
0.3 
1.15 
1.2 
1.25 
4.5 
3.3 
2.15 
2.3 
0.2 – 1.3 
36 
1)  
siRNA 
type 
Structure of siRNA Strand 
Length of the 
strand, nt 
1 
      5'-NNNNNNNNNNNNNNNNNNNNN-3' 
3'-NNNNNNNNNNNNNNNNNNNNN-5' 
sense 
antisense 
21 
21 
2 
      5’-NNNNNNNNNNNNNNNNNNN-3’ 
3’-NNNNNNNNNNNNNNNNNNNNN-5’ 
sense 
antisense 
19 
21 
2) Numeration of the nucleotides from the 5'-end. 
3) Substitutions in the sense strand are presented in normal letters; substitutions in the antisense strand are presented in 
italic. 
4) P.luciferase s (а) – a gene or a fragment of gene encoded sense (s) or antisense (a) RNA. 
5) АPPL(S)/luciferase – recombinant gene, containing mutant London (L) or Swedish (S) type of APP allele.  
b) Silencing activity of structurally modified siRNA is presented as the ration of IC50 (primary siRNA) / IC50 (modified 
siRNA), where IC50 is the concentration of siRNA, inducing –50 % silencing of the target gene. 
Table 4. The influence of the nucleotide substitutions in siRNA on the efficiency of RNAi 
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The elevation of the thermodynamic asymmetry by single nucleotide substitution at the 1th 
position of the antisense strand was reported to increase or have no influence on the silencing 
activity of  different siRNAs, targeted to sod1 / F.luciferase mRNA or the complementary 
sequence (antisense mRNA) [164] (Table 4). In turn, the equal efficiency of the cleavage of htt 
mRNA and htt antisense mRNA by thermodynamically symmetrical siRNA suggests the 
equal probability of sense or antisense strand incorporation into RISC* [38]. 
Introduction of the nucleotide substitutions at the 3’-end of the sense strand of siRNA 
duplex resulted in the formation of the mismatches, has led to the creation of the 
structurally new class of small interfering RNAs – fork-like siRNAs (fsiRNAs) [158]. More 
effective silencing of the expression of R.luciferase/P.luciferase gene by fsiRNAs then by 
classical siRNA targeted to the same sequences was demonstrated in Hela cells (Table 4). 
The most pronounced augmentation of the activity was observed for siRNA with initially 
moderate activity [158]. Fork-like siRNA with two nucleotide substitutions at the 3’-end of 
the sense strand was found to be the most active [11, 158, 159] (Table 4). Introduction of 
from 2 to 4 nucleotide substitutions at the 3’-end of the sense strand of siRNA targeted sod1 
and htt mRNAa correspondingly increased the efficiency of silencing [38].  
The increase of the thermodynamic asymmetry of the duplex by the introduction of the 
mismatches at the ends of the strands cannot guarantee the positive influence on the 
activity. It is known, that the region of the “guide” strand spanning from 2 to 6 position 
determines the efficiency of the interaction of siRNA with Ago2 [21, 30, 31]; this fact limits 
the introduction of substitutions in this region. Nevertheless, С→U substitution in 2d 
position of the antisense strand of siRNA targeted Jagged-1 mRNA increased the silencing 
effect from 0 to 50% in НЕК 293Т cells transfected with vector, containing cDNA fragment 
of the target gene [165] (Table 4). This data suggests, that the substitutions in the antisense 
strand resulted in the formation of non-canonical base pairs is more tolerable than the 
substitutions resulted in the formation of mismatches. In the other study, single nucleotide 
substitutions at 19th position of the sense strand or at the 1st position of the antisense strand 
resulting in the formation of the mismatches as well as non-canonical base-pairs reduced the 
activity of anti-EGFP siRNA in H1299 cells. It was assumed that the reduction of the 
efficiency of the interaction of TRBP (but not the Dicer) with siRNA was the possible reason 
of the observed effect [24] (Table 4). 
Introduction of nucleotide substitutions in the central part of siRNA duplex could be used for 
the destabilization the central region and the subsequent elevation of the silencing activity. 
Nevertheless, this type of structure modification could switch the mode of siRNA action to 
miRNA-like mechanism  [167] (fig. 4). It was demonstrated in experiments on HeLa cells, that 
substitutions in 9th and 10th positions of the sense strand of siRNA leads to the 2 - 4.5-fold 
increase of IC50 as compared with IC50 for siRNA with classical duplex 36. Substitutions in 
the sense strand or in both strands of siRNA [167] reduced the efficiency of RNAi (Table 4). 
Thus, the introduction of nucleotide substitutions could be successfully used for the design 
of siRNA characterized by favorable thermodynamic asymmetry and low thermostability of 
the central part of the duplex. This approach can be applied for the creation active siRNA 
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targeted to any desired sequence for silencing of mutated or chimerical genes. However, 
there is not enough data publish up to date for the formulation of the universal rules for the 
design of fork-like siRNA and siRNA with destabilized center, the activity of resulted 
siRNA cannot be predicted and should be determined experimentally. 
4.2. The influence of the siRNA overhangs structure on the efficiency of gene 
silencing 
2 - 3 nt overhangs at the 3’-ends of siRNA are a distinguishing feature of both natural siRNA 
generated by Dicer and synthetic siRNA [40, 45, 162]. The overhangs are important for the 
interaction of siRNA with PAZ-domens of Dicer and Ago2 [21, 27, 168]. However, the data on 
the activity of siRNA with blunt ends (with no overhangs) are rather contradictory: in 
mammalian cells the activity of this type of siRNA did not vary significantly from the activity 
of siRNA with 2-nt overhangs targeted to the same sequence [59] , controversially, in extracts 
from drosophila cells blunt ends siRNA were less active [40, 45]. The assumption that 
observed difference could be accounted for the difference in the mechanism of action of 
heterodimer Dicer-R2D2 in drosophila and its analogue Dicer-TRBP in humans [59], did not 
find the experimental support, since it was reported recently, that in HeLa S3 the activity of the 
blunt ended siRNA was similarly lower (60% silencing) than the activity of classical siRNA (80 
% silencing) [162]. Moreover, the presence of 2 nt overhang at the 3’-end of only one of the 
strands leads to the selection of this strand as a guide strand due to the preferential loading 
into RISC*[162]. The presence of the mismatches at the 5’-end of the antisense strand resulting 
in the formation of thermodynamically asymmetrical duplex increases the efficiency of the 
incorporation of antisense strand, containing 2 nt overhang, into RISC*. Efficient silencing of 
the target gene expression by fork-like structurally asymmetrical siRNA was achieved in a 
number of studies conducted on HeLa cells (Table 4, 2nd type of siRNA). 
It was found the 1 nt shortening of the overhang (1 nt overhang instead of 2) at the 3’ end in 
some cases did not affect significantly the silencing activity [40]. The sequential lengthening 
of the 3’-end overhang in the sense or the antisense strand up to 7 nt induced the substantial 
reduction of the silencing activity of siRNA [40], probably due to inefficient interaction of 
this siRNAs with PAZ-domen of Dicer [29]. siRNAs, containing overhangs at the 5’-ends of 
the duplex were inactive in RNAi [40], and induced side effects related to the PKR-mediated 
activation of the innate immunity [169].  
Therefore, exploitation of the structurally asymmetrical siRNAs, containing 2 nt overhang 
only at the 3’-end of the antisense strand together with the reduction of the thermodynamic 
stability of the duplex at the 5’-end region of the antisense strand could be successfully used 
in siRNA design for increasing the efficiency of RNAi.  
4.3. Single stranded analogous of siRNA (ss-siRNA) 
Before the discovery of RNAi, it was demonstrated that long (several hundred bases in 
length) single stranded RNA are capable of sequence specific silencing of the expression of 
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homologous genes in C.elegans [170]. Later, it was assumed that the minor fraction of 
dsRNA in the preparations of ssRNA obtained by in vitro transcription was the agent that 
silence the expression of the target genes 1. However, the ability of antisense, but not sense 
ssRNA (22 – 40 nt) to induce gene silencing was experimentally verified in C.elegans [171]. It 
was demonstrated that mRNA degradation induced by ssRNA proceeds via RISC* 
assembling (fig. 9) [131,122]. The evaluation of the silencing activity of anti-luciferase ss-
siRNA in HeLa cells demonstrated, that the required concentration of ss-siRNA was 8-fold 
higher, than the concentration of classical siRNA to reach the similar level of gene silencing. 
In the other report, it was shown, that the concentration of ss-siRNA essential for the RISC 
assembling was 10 – 100 higher than the concentration of double stranded siRNA analogous 
[122]. High sensitivity of single stranded RNA to ribonucleases [62], and less efficient 
interaction with the RNAi machinery proteins [131,122] were supposed to be the possible 
reasons of the lower efficiency of RNAi induction by ssRNA.    
Thus, the application of non-modified ss-siRNA as inhibitors of gene expression is not 
beneficial in comparison with double stranded siRNA.  
4.4. dsRNA (27-30-mers) as Dicer substrates  
During the search of the effective inductors of RNAi, able to silence target gene at low 
(nanomolar and lower) concentrations, it was found that dsRNAs  25-30 bp in length which 
are substrates of Dicer (here and after DsiRNA – Dicer-substrate siРНК), are significantly 
more active in comparison with “classic” or “conventional” siRNAs [161, 172, 173, 174]. To 
compare interfering activity of DsiRNA and conventional siRNA the duplexes of different 
length (21-30 bp) and structure (presence or absence of 3’ or 5’ dinucleotide overhangs) 
targeting EGFP were used [174]. The interfering activity of dsRNA was evaluated at 
concentration ranging from 50 pMol to 50 nMol using HEK293 cells transfected with the 
plasmid encoded EGFP. It was shown that at subnanomolar concentrations (50 pM – 200 
pM) DsiRNAs were significantly more active than siRNA. Among duplexes tested the 
DsiRNA 27 bp in length with blunt ends displays the highest interfering activity: this 
DsiRNA (1 nM) inhibited expression of the target gene by 95% (Table 5) while 
corresponding siRNA was almost inactive [174]. It turned out, that this DsiRNA (27 bp, 
blunt ends) is processed by Dicer yielding pull of different siRNAs 21bp in length. Seven 
siRNAs (21 bp with 3’-dinucleotide overhangs) generated by single-nucleotide shift along 
the EGFP mRNA sequence homologous to DsiRNA were synthesized to answer the 
question can the synthetic siRNA be as active as this particular DsiRNA. It was shown that 
at the concentrations 50 pM and 200 pM neither each synthetic siRNA nor pull of synthetic 
siRNAs silence expression of EGFP as efficiently as corresponding DsiRNA. Interestingly, in 
the case if DsiRNA was processed by Dicer in vitro and then transfected into the cells the 
silencing efficiency of this processed DsiRNA was similar to the activity of synthetic siRNAs 
[174]. It has been suggested, than after DsiRNA cleavage Dicer did not dissociated from the 
complex with DsiRNA and thus governed the mode of interaction of R2D2 (D.melanogaster) 
or TRBP (H.sapiens) and, as a consequence, the unequivocal orientation of siRNA within the 
RISC. This provides for incorporation into the RISC the antisense strand of the duplex. 
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However, if an equivocal binding of Dicer with dsRNA takes place which results in a 
formation of a set of siRNA cleavage products, the possibility of formation of incompetent 
RISC*, containing sense strand of siRNA as a leading strand is increased. Thus, optimization 
of a structure of DsiRNA is a current task. 
It is known, that one of the functions of Dicer within the cell is a processing of pre-miRNA 
via binding with their 3’-end, containing two hanging nucleotides followed by cleavage of 
the duplex at a distance of 21-22 nucleotides from the 3’-end [172]. Taking into account that 
Dicer has a low affinity to DNA, a set of asymmetric dsRNA was synthesized, containing at 
the 3’-end of the sense or antisense strand two nucleotides overhang, while the opposite end 
was blocked for Dicer binding by the replacement of two ribonucleotides in the 
complementary strand by deoxyribonucleotides [161, 172] (Table 5, structures 25D/27 and 
27/25D). It was anticipated that such a structure of DsiRNAs provide for an unequivocal 
binding of the duplex with Dicer.  
According to mass-spectrometry the cleavage of these DsiRNA by Dicer (Table 5, structures 
25D/27 and 27/25D) yields the same product in both cases [161]. However, the silencing 
activity of siRNAs derived from these DsiRNAs was different; which possibly is explained 
by the peculiarities of DsiRNA interactions with Dicer, determined the efficiency of sense or 
antisense incorporation into RISC*. 
 
Target gene / model system Optimal or the only 
studied concentration 
of DsiRNA, nM 
DsiRNA structure 
peculiarities 
Level of target gene 
silencing, % 
Ref 
 
EGFP, 
Plasmid DNA encoded 
EGFP transfected in НEK 
293 cells 
50 21+2 1) 
23-2 
23+2 
24-2 
24+2 
25-2; 25+2; 26+0; 
27+0; 27+2; 27-2 
72 
80 
98 
82 
95 
~ 100 
 
174 
EGFP, 
Endogenous gene in 
NIH3T3 cells 
1 27+0 
30+0 
35+0 
40+0 
45+0 
98 
98 
97 
2 
<1 
EGFP, 
Plasmid DNA encoded 
EGFP transfected in НEK 
293 cells 
1 19+2 
27+0 
27/25D 2) 
25D/27 
<1 
68 
53 
95 
 
161 
F.luciferase 13),
Plasmid DNA transfected in 
НEK 293 cells 
10 27/25D 
25D/27 
80 
97 
F.luciferase 23)
Plasmid DNA transfected in 
НEK 293 cells
27/25D 
25D/27 
97 
96 
F.luciferase 33)
Plasmid DNA transfected in 
НEK 293 cells 
27/25D 
25D/27 
23 
78 
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Target gene / model system Optimal or the only 
studied concentration 
of DsiRNA, nM 
DsiRNA structure 
peculiarities 
Level of target gene 
silencing, % 
Ref 
 
F.luciferase 43)
Plasmid DNA transfected in 
НEK 293 cells 
27/25D 
25D/27 
95 
94 
La antigene in
НЕК 293 cells 
10 27/25D 
25D/27 
30 
82 
172 
STAT1, endogenous gene in 
HeLa cells 
1 25D/27 95 173 
1) The structures of dsRNA – substrates of Dicer:  L+2 – duplex of L bp with two nucleotide overhangs at the 3’- ends, 
L–2 – duplex of L bp with two nucleotides overhangs at the 5’ ends, L+0 – duplex of L bp with blunt ends where L 
varied from 19 to 45 bp. 
The structure 
of DsiRNA 
Scheme of DsiRNA Length of the strand (L), bp 
L+2 
  5’– NNNNNNNNNNNNNNNNNNNNNNN-3’ 
3’– NNNNNNNNNNNNNNNNNNNNNNN-5’ 
23 
23 
L-2 
5'-NNNNNNNNNNNNNNNNNNNNNNNN-3' 
  3'-NNNNNNNNNNNNNNNNNNNNNNNN-5' 
24 
24 
L+0 
5’-NNNNNNNNNNNNNNNNNNNNNNNNNN-3’ 
3’-NNNNNNNNNNNNNNNNNNNNNNNNNN-5’ 
26 
26 
2) Asymmetric DsiRNA (25 bp), containing at the 3’-end of the sense (antisense) strand 2 nt overhang, the opposite end 
was blocked by replacement of two ribonucleotides with deoxyribonucleotides – N. 
 
The structure 
of DsiRNA 
Scheme of DsiRNA Strand 
Length of the 
strand (L), bp 
27/25D 
5’-NNNNNNNNNNNNNNNNNNNNNNNNNNN-3’ 
3’-NNNNNNNNNNNNNNNNNNNNNNNNN-5’ 
sense 
antisense 
27 
25 
25D/27 
      5’-NNNNNNNNNNNNNNNNNNNNNNNNN-3’
3’-NNNNNNNNNNNNNNNNNNNNNNNNNNN-5’ 
sense 
antisense 
25 
27 
3) The numbers correspond to different sequences within the target gene F.luciferase.    
Table 5. The influence of DsiRNA structure in its silencing activity 
It was shown, that in HEK293 and HeLa cells the DsiRNAs with antisense strand having 
dinucleotide overhang at the 3’-end were more active than those with dinucleotide 
overhang at the 3’-end of the sense strand (Table 5) [161, 172]. Thus, it is possible to predict 
the structure of forming siRNAs upon processing of DsiRNA by Dicer [161, 172], however, 
the activity of these siRNAs will depend on the thermodynamic parameters of their 
duplexes. It worth mentioning that in the case of unfavorable context of the target sequence 
within mRNA DsiRNAs have a significant advantage over conventional siRNA [174].  
The silencing activity of a longer dsRNAs with blunt ends (27 – 45 bp) decreases with the 
increase of dsRNA length. It turns out that this drop of silencing activity correlate well with 
the drop of efficiency of cleavage of longer dsRNAs by Dicer [174]. The silencing effect 
caused by DsiRNA was longer in comparison with conventional siRNA: DsiRNAs 
efficiently silence EGFP expression in NIH3T3 cells for 10 days while corresponding siRNA 
displays silence activity not longer than 4-7 days [174].  
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Despite the promising results on silence activity of Dicer substrates the optimization of the 
properties of DsiRNAs by chemical modification is relevant. The influence of 2’-F- and 2’-O-
Mе modifications within DsiRNA type 25D/27 on the silencing activity and nuclease 
resistance was studied [173]. When choosing sites of modifications authors try to avoid the 
region needed for Dicer to execute dsRNA cleavage, despite presence there of nuclease 
sensitive motives (Fig. 11).  
 
Figure 11. Design of chemically modified DsiRNA. By bold letter N deoxyribonucleotides are shown, 
short arrows – cleavage site of DsiRNA by Dicer. 
It was shown, that chemical modification of DsiRNA affects its silencing activity in respect 
to STAT1 mRNA only at the lowest concentration used (100 pM), while at higher 
concentration of DsiRNA (1 and 10 nM) the drop of silencing activity was detected only for 
extensively modified molecules, containing combination of several 2’-F- and 2’-O-Me 
nucleotides in a row. DsiRNA containing 11 2’-O-Me nucleotides in the antisense strand was 
very nuclease resistant: the fraction of intact DsiRNA was found in reaction mixture after 24 
h of incubation in the presence of serum. However, such an extensive modification affects 
pattern of DsiRNA cleavage by Dicer and lead to the formation of two products of 21 and 22 
bp instead of one product of 21 bp formed with unmodified DsiRNA. Replacement of one or 
two 2’-O-Me nucleotides in the vicinity of Dicer cleavage sites by the natural ones facilitated 
formation of 21 bp cleavage product. The introduction from 1 to 4 mismatches into central 
part of each strand of anti-EGFP DsiRNA significantly reduced its silencing activity [174].  
On the other hand, chemical modification of DsiRNA can block induction of the unspecific 
immune response in mammalian cells, linked with the presence of triphosphate groups at 
the 5’ ends of DsiRNA or/and immunostimulating motives in the duplex [43,175, 176, 177, 
178, 179,180]. So, DsiRNA, which contains in the antisense strand 10 -11 2’-O-Me nucleotides 
(including 2’-O-Me-cytidine and 2’-O-Me-uridine nucleotides known as the most effective 
blockers of interferon response activation via endosomal TLR [64]), blocked IFN-α secretion 
by human PBMC and did not induce immune response in RIG-I-dependent T98G cells 
opposite to unmodified DsiRNA and 2’-F-modified disРНК, respectively [173].  
Full replacement of natural nucleotides by the analogs (2’-O-Me, 2’-F, etc.) is unacceptable as 
these DsiRNA will not be processed by Dicer [173]. Therefore, upon the introduction of 
chemical modifications in the structure of DsiRNA one should avoid modifying the 
nucleotides from 1 to 8 from 5’ end of the sense strand and complementary region of the 
sense strand (Fig. 11). Moreover, two overhanging nucleotides at the 3’-end of the antisense 
 
Structure - Functions Relations in Small Interfering RNAs 215 
strand as well as two deoxyribonucleotides at the 3’-end of the sense strand facilitate the 
correct orientation of Dicer and selection of  the antisense strand of DsiRNA as a leading 
strand. 
4.5. Small segmented RNA 
Recently another approach to enhance RNAi efficiency based on modification of siRNA 
structure was proposed [99]. It was shown that siRNA in which the sense strand is 
subdivided in two parts of 10-12 nucleotides long, are more active in comparison with 
conventional siRNA duplexes. The efficiency of this internally segmented siRNA or sisiRNA 
(small internally segmented interfering RNA) (Fig. 9) was provided by unequivocal 
incorporation of the antisense strand into RISC*, since the nick in the central part of the 
sense strand blocked its usage as a guiding strand and facilitate the dissociation of the sense 
strand from the duplex [99]. Thus, sisiRNA have an advantage over conventional siRNA 
with unfavorable duplex thermoasymmetry. In addition unlike siRNAs with the classic 
structure the extensive chemical modification of antisense strand of sisiRNA has only little 
effect on its silencing activity. As an example, the silencing activity of anti-EGFP sisiRNA 
with antisense strand having 6 LNA-nucleotides or alternative 2’-F / 2’-O-Me-nucleotides 
and internally segmented sense strand with 6 LNA-nucleotides in each part was 
significantly higher than that of conventional siRNA bearing the same modifications [99]. 
Besides, both mentioned sisiRNA display high nuclease resistance. Thus, sisiRNAs as 
sequence specific inhibitors of gene expression are very promising, because they provide 
efficient RNAi even at the unfavorable thermodynamic parameters RNA duplex. 
According to literary data the structural and thermodynamic peculiarities of interfering 
RNAs are a major factors providing for efficient gene silencing.  
Prediction of silencing activity of any siRNA based on its thermodynamic profile is an 
efficient method of selection of active molecules. This approach is used in a number of 
software and algorithms for search and selection of such siRNA [37]. An alternative 
approach to the problem of creating efficient sequence-specific inhibitors of gene expression 
is the use of structure-modified siRNAs: fork-like siRNAs, DsiRNAs, or sisRNAs which 
silencing activity is less dependent on their thermodynamic parameters as compared with 
conventional siRNA diplex.  
5. Conclusion 
Small interfering RNAs are not optimal to be used as therapeutics in vivo, therefore, 
development of the approached aimed to improve or/and optimize the properties of siРНК 
is of significance nowadays. One of the approaches widely used is chemical modification of 
siRNAs. At the beginning this approach was proposed as a way to increase nuclease 
resistance of siRNA in the presence of serum, in the cells and bloodstream [61, 62]. The 
enhancement of nuclease resistance of siRNA by chemical modification not resulting in the 
drop of its silencing activity represent a complex task, since silencing activity of siRNA is 
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strongly affected by the nature, number and locations within the duplex of chemical 
modifications [65, 76, 181]. Despite many works carried out in this area, a general algorithm 
which allows receiving active nuclease resistant siRNA is not developed yet.  
Chemical modification of siRNA can be also used to develop delivery vehicles for siRNA. It 
is well known that naked or free siRNA is not able to penetrate through cellular membrane 
and accumulate in the cells. In the case of in vivo conditions, the small size of siRNA 
molecule promotes its rapid clearance [57]. In other words, the systems for in vivo delivery 
of siRNAs should provide for efficiency of cellular accumulation, specificity of delivery (if 
applicable), duration of silencing as well as safety and possibility of systemic 
administration. Today no one delivery approach encounters these criteria.  
On the other hand, the low efficiency of RNAi can be a result of its unfavorable sequence 
determining thermodynamic properties and/or by stable secondary structure at the target 
site within mRNA [37, 38, 51, 52, 54]. There are several algorithms to select siRNAs of high-
performance [182, 183, 184, 185, 186], however it is impossible to predict precisely silencing 
activity of any particular siRNA in vivo. In addition, the design of siRNA targeting chimeric 
or mutant genes represent of complex task since the limitations of target site selection does 
not allow to use these algorithms for choosing the sequence siRNA. This is why structure 
modifications of siRNA improving their thermodynamic properties are of interest. The fork-
like siRNA [158, 159], able to silence target gene more efficiently that conventional siRNA is 
a promising approach for creating high-performance siRNA targeted any sequence of the 
gene. Despite this, the number of works in this field is negligible so further research of 
properties of siRNA with modified structure are relevant. 
To obtain high-performance siRNA often optimization of multiple parameters is required, 
so using modification of the siRNA structure together with its chemical modification is a 
promising approach. Thus, advanced research of chemically and/or structurally modified 
siRNA, as well as development and optimization of the algorithms for modification are 
important. 
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